Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Accumulated Depreciation: 2017-2025

Historic Accumulated Depreciation for Aclaris Therapeutics (ACRS) over the last 9 years, with Sep 2025 value amounting to $5.0 million.

  • Aclaris Therapeutics' Accumulated Depreciation rose 6.50% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year increase of 6.50%. This contributed to the annual value of $4.8 million for FY2024, which is 15.45% up from last year.
  • Latest data reveals that Aclaris Therapeutics reported Accumulated Depreciation of $5.0 million as of Q3 2025, which was down 0.52% from $5.0 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Accumulated Depreciation registered a high of $5.0 million during Q2 2025, and its lowest value of $2.9 million during Q1 2021.
  • Moreover, its 3-year median value for Accumulated Depreciation was $4.6 million (2023), whereas its average is $4.6 million.
  • Data for Aclaris Therapeutics' Accumulated Depreciation shows a peak YoY increased of 29.36% (in 2021) over the last 5 years.
  • Over the past 5 years, Aclaris Therapeutics' Accumulated Depreciation (Quarterly) stood at $3.4 million in 2021, then grew by 18.92% to $4.0 million in 2022, then climbed by 3.15% to $4.2 million in 2023, then increased by 15.45% to $4.8 million in 2024, then grew by 6.50% to $5.0 million in 2025.
  • Its Accumulated Depreciation stands at $5.0 million for Q3 2025, versus $5.0 million for Q2 2025 and $4.9 million for Q1 2025.